Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
VEGF inhibitor
Biotech
Kalaris pauses eye drug trial to resolve ocular inflammation
Kalaris Therapeutics has paused a phase 1 study of its next-gen eye drug while it attempts to finally resolve cases of eye inflammation.
James Waldron
Mar 11, 2026 6:30am
Instil refills pipeline in $2B biobucks deal with ImmuneOnco
Aug 1, 2024 10:19am
ASCO: Chi-Med touts fruquintinib's phase 3 safety edge
Jun 5, 2017 6:24pm
Aveo takes baby step forward for once-rejected tivozanib
Feb 23, 2017 10:23am
